Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, Yunha | - |
dc.contributor.author | Kim, Ho Cheol | - |
dc.contributor.author | Kim, Young-Chul | - |
dc.contributor.author | Jang, Seung Hun | - |
dc.contributor.author | Lee, Kye Young | - |
dc.contributor.author | Lee, Shin Yup | - |
dc.contributor.author | Lee, Sang Hoon | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Yoon, Seong Hoon | - |
dc.contributor.author | Ryu, Jeong-Seon | - |
dc.contributor.author | Jang, Tae Won | - |
dc.contributor.author | Chang, Yoon Soo | - |
dc.contributor.author | Kim, Seung Joon | - |
dc.contributor.author | Park, Chan Kwon | - |
dc.contributor.author | Lee, Jeong Eun | - |
dc.contributor.author | Jung, Chi Young | - |
dc.contributor.author | Choi, Chang-Min | - |
dc.date.accessioned | 2021-11-23T06:40:22Z | - |
dc.date.available | 2021-11-23T06:40:22Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128443 | - |
dc.description.abstract | Background In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy. Methods This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017. Patients with adenocarcinoma with EGFR mutation who underwent rebiopsy and were treated with EGFR-TKIs were included. Results Of a total of 352 patients, T790M mutation was identified in 156 (41.9%) at the time of rebiopsy. The median duration from initial biopsy to rebiopsy was 17 months. Univariate logistic regression analysis revealed associations of exon 19 deletion (odds ratio [OR], 1.643; p = 0.026), absence of L858R (OR, 0.627; p = 0.042), and previous EGFR-TKI treatment duration (OR, 1.039; p < 0.001) with T790M mutation. Previous EGFR-TKI treatment duration (OR, 3.580; p < 0.001) was independently associated with T790M mutation. A multivariate Cox proportional hazard model revealed that brain metastasis at initial diagnosis (hazard ratio, 1.390; p = 0.050) tended to be associated with T790M mutation. Among the patients with T790M mutation at rebiopsy, the osimertinib user group (n = 90) had a better one-year survival (68.7 vs. 58.3%, p = 0.048) than the osimertinib nonuser group (n = 66). Conclusions Rebiopsy might affect the clinical course of patients with EGFR-mutant adenocarcinoma who receive EGFR-TKIs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sung Yong | - |
dc.identifier.doi | 10.1111/1759-7714.13857 | - |
dc.identifier.scopusid | 2-s2.0-85100223416 | - |
dc.identifier.wosid | 000613886500001 | - |
dc.identifier.bibliographicCitation | THORACIC CANCER, v.12, no.6, pp.890 - 898 | - |
dc.relation.isPartOf | THORACIC CANCER | - |
dc.citation.title | THORACIC CANCER | - |
dc.citation.volume | 12 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 890 | - |
dc.citation.endPage | 898 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordAuthor | lung cancer | - |
dc.subject.keywordAuthor | EGFR& | - |
dc.subject.keywordAuthor | #8208 | - |
dc.subject.keywordAuthor | TKI | - |
dc.subject.keywordAuthor | acquired resistance | - |
dc.subject.keywordAuthor | T790M | - |
dc.subject.keywordAuthor | rebiopsy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.